Dehydroepiandrosterone sulfotransferase converts dehydroepiandrosterone (DHEA) and some other steroids to their sulfonated forms. The human enzyme has been crystallized in the presence of substrate (DHEA) alone, in the presence of substrate and nonsulfated cofactor analogue (PAP) and in the absence of both substrate and PAP in our laboratory, with data sets collected at a synchrotron source. The crystals of the uncomplexed form belong to the orthorhombic space group C222 1 , with unit-cell parameters a = 85.26, b = 87.69, c = 108.20 A Ê and data 99.2% complete to 2.35 A Ê resolution. The DHEA complex crystallizes in the orthorhombic space group P2 1 2 1 2, with unit-cell parameters a = 74.46, b = 127.49, c = 44.59 A Ê and data 92.9% complete to 2.15 A Ê resolution. The ternary complex crystallizes in the orthorhombic space group P2 1 2 1 2 1 , with unit-cell parameters a = 62.25, b = 87.28, c = 138.86 A Ê and data 98.6% complete to 2.50 A Ê resolution. Preliminary molecular-replacement solutions indicate signi®cant variations in dimer formation.
Introduction
In humans, the adrenal gland secretes large amounts of dehydroepiandrosterone sulfate (DHEA-S) and dehydroepiandrosterone (DHEA) throughout adult life (Labrie, 1991) . Although DHEA-S and DHEA levels are higher than any other steroids except cholesterol, they do not have intrinsic biological activity. After circulation to peripheral target tissues, they are ®rst converted to androstenedione (Á4-dione) and then to either active androgens or estrogens (Adams, 1985; Labrie et al., 1985) . The Á4-dione can either be transformed into androgenic testosterone (T) or dehydrotestosterone (DHT) or into estradiol (E 2 ) depending upon the levels of 17-hydroxysteroid dehydrogenase (17-HSD), 3-hydroxysteroid dehydrogenase (3-HSD), 5-reductase and aromatase activities present in the different peripheral tissues. In postmenopausal and young women, 80±100% of androst-5-ene-3,17-diol (Á5-diol), another important estrogen, is converted directly from DHEA by 17-HSD. Thus, DHEA-S and DHEA as well as Á4-dione are considered to be precursor sex steroids. It is estimated that about 30±50% of androgens in men and the majority of estrogens in women (75% and close to 100% for those post-menopause) are produced in peripheral tissues from precursor steroids of adrenal origin (Labrie, 1991) .
There is increasing interest in steroid sulfonation studies, especially the production of DHEA-S. Sulfonation generally results in the detoxi®cation of chemical compounds, as it decreases the hydrophobicity of the steroids (Jakoby et al., 1980) . DHEA-S, which is the main circulating form of DHEA, has also been shown to be much more stable than DHEA (Longcope, 1996) . The enzyme dehydroepiandrosterone sulfotransferase (DHEA-ST; E.C. 2.8.2.2.) catalyzes the sulfonation of DHEA on the 3 oxygen with 3 H -phosphoadenosine-5 H -phosphosulfate (PAPS) as a cofactor. DHEA-ST has been characterized from different sources; for example, from rodent, guinea pig, bovine and human liver, and from bovine and human adrenal tissues (Gura et al., 1990; Demyan et al., 1992; Oeda et al., 1992; Driscoll et al., 1993; Wilborn et al., 1993; Luu-The et al., 1996 .) The function and the regulation of human DHEA-ST have been extensively studied Luu-The et al., 1996; Parker et al., 1995 Parker et al., , 1998 . The crystal structure of the human form of this enzyme has been solved by X-ray crystallography (Pedersen et al., 2000) . Although the enzyme crystallized in the presence of both the desulfonated cofactor (PAP) and the preferred substrate, the substrate was excluded from the active site by protein-loop conformations. We began the study before the structure was published and continue with the intention of more closely examining substrate binding and the relationship between cofactor and substrate. The three-dimensional structure of a related enzyme estradiol sulfotransferase crystallization papers complexed with substrate and cofactor analogues has been solved by X-ray diffraction (Kakuta et al., 1997) .
Following the cloning and characterization of the DHEA-ST gene (Luu-The et al., 1995) , we have overexpressed it in Escherichia coli and puri®ed DHEA-ST to homogeneity (Luu-The et al., 1995; Chang et al., 2001) . Here, we report the crystallization and preliminary X-ray diffraction results of this enzyme in an apo form and cocrystallized with DHEA alone and as a DHEA±PAP±enzyme ternary complex.
Materials and methods
Human DHEA-ST was puri®ed in our laboratory. Brie¯y, recombinant human dehydroepiandrosterone sulfotransferase expressed as a glutathione sulfotransferase fusion protein in E. coli was puri®ed using glutathione Sepharose 4B af®nity chromatography, a Factor Xa cleavage step and Q-Sepharose Fast Flow column chromatography (Chang et al., 2001) . The substrate DHEA, the detergent n-octyl -d-glucopyranoside (-OG) and chemicals such as trizma base (Tris After puri®cation, human DHEA-ST was concentrated to 20±25 mg ml À1 (determined by the Bio-Rad protein assay method; Bradford, 1976) in a buffer containing 10 mM Tris pH 7.5, 0.5 mM EDTA and 0.1% -OG using a Centricon 30K. The concentrated enzyme can be stored at 277 K for at least one month. Crystallization of DHEA-ST and its complexed forms were carried out in parallel using the hanging-drop method of vapour diffusion (McPherson, 1999) with the sparse-matrix kits I and II (Jancarik & Kim, 1991) for condition screening. The initial conditions for the three forms were found with the ®rst attempt, i.e. sparse-matrix screening kit I No. 17 for DHEA-ST alone, sparse matrix II No. 25 for DHEA-ST±DHEA and sparse matrix II No. 37 for DHEA-ST± DHEA±PAP. The conditions were then optimized.
The X-ray diffraction analyses of the three crystal forms were carried out at the X8C beamline at the National Synchrotron Light Source, Brookhaven National Laboratory, Upton, New York, USA using a Quantum-IV CCD imaging-plate detector. The data sets were collected under cryoconditions. All crystal forms used glycerol and mineral oil as cryoprotectant.
Molecular replacement and map calculation were carried out with the CNS software package (Brunger et al., 1998) . Models and maps were visualized with O (Jones et al., 1991) . The human DHEA-ST structure in complex with PAP (Pedersen et al., 2000) was used as the search model.
Results
DHEA-ST crystals were obtained by mixing 2.4 ml of enzyme solution with 2.4 ml reservoir solution in the hanging drop. The enzyme stock concentration was 20 mg ml À1 and the reservoir contained 100 mM Tris pH 8.5, 250 mM (NH 4 ) 2 SO 4 and 27.5% PEG 4000. The crystals appeared in 2 d and grew to dimensions of 0.25 Â 0.25 Â 0.25 mm ( Fig. 1a ) after 7±10 d. Crystals were moved through mineral oil before being¯ashfrozen on the beamline. These trapezoidal crystals are C-centered orthorhombic, with unit-cell parameters a = 85.26, b = 87.69, c = 108.20 A Ê . Data were collected from a single crystal 180 mm from the detector. Since the mosaicity was determined to be approximately 1 , an oscillation angle of 2 for each image was chosen. A total of 92 images were collected and processed using the HKL package (Otwinowski & Minor, 1997) . Although the data were nearly 100% complete at 2.22 A Ê , with the last resolution shell having an I/'(I) value greater than 2, the R sym of the last resolution shell was too high. The resolution was lowered to 2.35 A Ê , as the R sym value for this shell was more reasonable. The ®nal R sym was 6.3% with data 99.2% complete. Based on systematic absences, the space group was determined to be C222 1 . The data collection is summarized in Table 1 . V M was calculated to be 2.99 A Ê 3 Da À1 (Matthews, 1968) , assuming one subunit in the asymmetric unit and a calculated subunit mass of 33 794 Da. The solvent content of the crystal was therefore calculated to be 59%. The molecularreplacement translation function gave a single solution 3.7' greater than the second peak. This solution corresponded to the strongest peak of the rotation function.
The DHEA-ST was also cocrystallized with DHEA in a hanging-drop method by vapor diffusion. The reservoir contained 100 mM Tris pH 7.5, 1.2 mM CoCl 2 and 170 mM (NH 4 ) 2 SO 4 . The protein stock contained 12 mg ml À1 (0.35 mM) DHEA-ST and 0.5 mM DHEA in the buffer described in x2. The hanging-drop crystallization was initiated by adding 1.8 ml of protein to 2.7 ml crystallization papers of reservoir solution. The crystals appeared after 2±3 d and matured in 7±10 d. 80% glycerol (1.5 ml) was added to the drop before the crystals were passed through mineral oil and¯ash-frozen on the beamline. These crystals have a thick plate shape ( Fig. 1b) and are primitive orthorhombic, with unit-cell parameters a = 74.46, b = 127.49, c = 44.59 A Ê . Data were collected from a single crystal 160 mm from the detector. The mosaicity of these crystals was determined to be approximately 0.4 and therefore a 1 oscillation angle was chosen. A total of 94 images were collected and processed using the HKL package (Otwinowski & Minor, 1997) . Data were processed to 2.15 A Ê with an R sym of 4.9% and a completeness of 92.9%. Using a resolution cutoff based on a minimum I/'(I) of 2 for the last resolution shell, a slightly higher resolution value was possible with good completeness and a reasonable R sym for the last resolution shell. Based on systematic absences, the space group was determined to be P2 1 2 1 2. The data collection is summarized in Table 1 . V M was calculated to be 3.13 A Ê 3 Da À1 (Matthews, 1968) , assuming one subunit in the asymmetric unit. The solvent content of the crystal was therefore calculated to be 61%. The molecular-replacement translation function gave a single solution 6.4' greater than the second peak. The solution corresponded to the strongest rotation peak.
DHEA-ST was also cocrystallized as a ternary complex with DHEA and the nonsulfonated cofactor analogue (PAP) by the hanging-drop method of vapour diffusion. The reservoir contained 100 mM sodium acetate pH 4.6 and 8% PEG 4000. The protein stock contained 14 mg ml À1 DHEA-ST and 4 mM PAP in the buffer described in x2. The crystallization in hanging drops was initiated by mixing 1.5 ml of protein with 1.5 ml of reservoir solution and then adding 0.225 ml of 5 mM DHEA. The crystals reached full size in 3±4 d. As cryoprotectant, 80% glycerol was added to the drop to a ®nal concentration of 20%, after which the crystals were passed through mineral oil and¯ash-frozen on the beamline. These crystals have a thick irregular shape (Fig. 1c) and are primitive orthorhombic, with unit-cell parameters a = 62.25, b = 87.28, c = 138.86 A Ê . Data were collected from a single crystal 180 mm from the detector. The mosaicity of these crystals was determined to be approximately 0.5 and therefore a 1 oscillation angle was chosen. A total of 84 images were collected and processed using the HKL package (Otwinowski & Minor, 1997) . Data were processed to 2.50 A Ê with an R sym of 6.7% and a completeness of 98.6%. Using a resolution cutoff based on a minimum I/'(I) of 2 for the last resolution shell gave good completeness and a reasonable R sym for the last resolution shell. Based on systematic absences, the space group was determined to be P2 1 2 1 2 1 . The data collection is summarized in Table 1 . V M was calculated to be 2.79 A Ê 3 Da À1 (Matthews, 1968) , assuming two subunits in the asymmetric unit. The solvent content of the crystal was therefore calculated to be 56%. Two molecular-replacement translation-function solutions (3.0 and 2.7' greater than the third peak) corresponding the two subunits in the asymmetric unit were obtained. These solutions corresponded to the two strongest rotation-function peaks.
Discussion
Human DHEA-ST is the enzyme involved in the sulfonation of the steroid DHEA to form DHEA-S. The latter is more stable, binds better to albumin and has a higher hydrophilicity than its non-sulfonated counterpart. In the transport of this important precursor steroid from adrenal origin to periphery tissue, DHEA-S is the major circulating form in the blood.
As DHEA and DHEA-S are the precursors of the steroid hormones such as DHT, T, E 2 and Á5-diol, dysfunction of DHEA-ST could lead to high levels of DHEA in the plasma and thus lead to dysfunction of the above important steroids. The abnormal regulation of the hormones may lead to sexhormone-dependent tumours or diseases such as estrogen-related breast cancer and androgen-related prostate cancer. It has been reported that hyperandrogenicity in women is associated with high levels of DHEA arising from non-classical 3-HSD de®ciency. However, there is no evidence of mutations for the type 1 and type 2 3-HSD genes (Luu-The et al., 1996; Ze Â rah et al., 1994) and therefore dysfunction of DHEA-ST is a potential candidate for causing familial hyperandrogenicity. There is some evidence linking DHEA and DHEA-S to cardiovascular disease (Khaw, 1996) and it has also been reported that reduced hepatic content of DHEA-ST is related to chronic liver disease (Elekima et al., 2000) . Structural knowledge of DHEA-ST, especially in relation to substrate binding, will give us an opportunity to study in detail the mechanism of these diseases and the role of this enzyme in regulating sex hormones in the human body.
The structure of the binary complex of DHEA-ST and its cofactor analogue was recently reported by Pedersen et al. (2000) . Even though these crystals were grown under saturating concentrations of DHEA, there was no substrate found at the active site. This has been attributed to the presence of a loop that penetrates the active site in a conformation stabilized through dimer interactions. Pedersen et al. (2000) suggest that it represents the physiological dimer in an inactive state. Although their crystallization conditions are quite different (0.8 M citrate, 80 mM cacodylate pH 5.75), the space group of the enzyme cocrystallized in the presence of both DHEA and PAP by our group is the same as that achieved by Pedersen et al. (2000) , differing by an increase of approximately 10 A Ê in each unitcell parameter. An examination of the crystal packing showed that the dimer interactions are essentially the same and the initial maps show clear density from the cofactor analogue and the active-site penetrating loop. Even though our crystals were grown in the presence of saturating DHEA Table 1 Data-processing statistics.
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there was no substrate density found in the active site. A possible consideration is that the pre-mixing of the non-cognate cofactor and protein before the addition of DHEA may affect the substrate binding. DHEA-ST crystals obtained through the cocrystallization with DHEA were immediately destroyed when exposed to PAP, suggesting a possible conformational change upon binding of the non-cognate cofactor. An examination of the packing of the three crystal forms of DHEA-ST described in this paper shows that the dimer arrangement described above for the PAPcontaining crystal form (P2 1 2 1 2 1 ) is not found in either the DHEA-containing (P2 1 2 1 2) and apo (C222 1 ) crystal forms. The three-dimensional structure of a related enzyme, estradiol sulfotransferase (EST), complexed with substrate and cofactor analogues has been solved by X-ray diffraction (Kakuta et al., 1997) . The overall protein fold is very similar, although the enzymes have different substrate speci®cities and the sequence identity is quite low at 37.6%. The EST dimer differs from thè inactive dimer' of DHEA-ST described by Pedersen et al. (2000) by a 110 rotation of one of the monomers. It is possible that the latter dimer arrangement (non-crystallographic) may have been a consequence of crystal packing and that the true biological dimer was de®ned by crystallographic symmetry. A comparison of the DHEA cocrystallized form with the PAP cocrystallized form shows just such a relationship, requiring an approximately 10 rotation in one direction for the two monomers to overlap, although in these cases the degree of interaction is not so strong as seen with the so-called`inactive dimer'. The apo enzyme crystal form (C222 1 ) would require some translation but little rotation for overlap to occur. This would be far less rearrangement than would be necessary to convert the`inactive dimer' of DHEA-ST/ PAP to the dimer arrangement described in EST (Kakuta et al., 1997) . The determination of which arrangement constitutes the biological dimer requires further study.
Our preliminary results indicate that the crystal packing of the DHEA-ST crystallized in the presence of DHEA alone is signi®cantly different from that crystallized in the presence of DHEA and PAP. The dimer interactions, which stabilize the active-site penetrating loop, are not present in the former structure; preliminary examination indicates signi®cant changes in the active site, including the possibility of substrate binding. Work is in progress to re®ne these structures in order to examine the relationship between substrate and cofactor binding to the monomer and dimer arrangement. A comparison of substrate binding with that seen with estradiol sulfotransferase will lead to a more complete understanding of steroid sulfonation in general. The study of struc-ture±function relationships of DHEA-ST would lead to a more complete understanding of the synthesis of these important precursor steroids and the related function of androgens and estrogens.
